Home / Pharmaceutical / BioPharmaceutical Industry in China - An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges

BioPharmaceutical Industry in China - An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges

Published: May 2013 | No Of Pages: 105 | Published By: Kelly Scientific Publications

Product Synopsis

 
BioPharmaceutical Industry in China - An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges” provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 154 tables & figures. The Chinese biopharmaceutical market is presented as follows:
 
By Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN, SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK, NOVARTIS)
By Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)
 
A wealth of financial information is provided including:
 
  • Company financials, sales & revenue figures
  • China GDP, economic growth, export (bulk drug, formulations) figures
  • Indian health expenditure as a function of GDP
  • Growth change figures of emerging and developing countries (India, Russia, China, Brazil)
  • Economic growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain, Japan, Canada)
  • Projected figures of strategic emerging industry GDP percentage contribution
 
SWOT, Economic and Business Environment specifics include:
 
  • Key strengths, weaknesses and threats influencing leading player position within the market
  • Top Five Contract Pharmaceutical Export Markets of China
  • Major players within China’s leading therapeutic markets (e.g., cancer, allergy, liver disease)
  • Multinational penetration into the Chinese Pharma Market
  • Comprehensive product portfolios, R&D activity and pipeline therapeutics 
  • M&A activity and future strategies of top Chinese pharmacos
  • Economic indicators, trade policy, merchandise and commercial trade statistics
  • Gross Domestic Product of China, historic and projection analysis
  • Chinese economic outlook in comparison to advanced economies 
  • Three Tier ‘Pharmerging’ Markets with Potential for Significant Growth 
  • Prescription drug sales distribution channels in China
  •  Major biogeneric products in China
This report highlights a number of significant Chinese and multinational pharmacos and gives details of their operations, products, financials and business strategy.
 
Amoytop Biotech
  • Active Pharmaceutical Products
  • Beijing Continent Pharmaceuticals
  • FusoGen Pharmaceuticals
  • Shanghai Huaguan Biochip
  • SiBiono GeneTech
  • Abbott
  • AstraZeneca
  • Boehringer Ingelheim
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson Medical
  • Merck
  • Novartis
  • Pfizer
  • Roche
 
 
Forecast projections and future growth rates are provided to give you a forthcoming perspective of this growing industry. Current developments relating to patent expirations, government funding, and regulations are discussed.  The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed. 
 
What you will gain:
 
  • An in-depth understanding of the Chinese biopharmaceutical market and it’s environment
  • Current market facts, figures and product lines of key players in the industry
  • An insight into how generic therapeutics will propagate the Chinese biopharmaceutical market
  • Knowledge of how the Chinese biopharma market will integrate into the global healthcare market 
  • Information on key regulatory and government policies 
  • Data on levels of private and publically funded biopharma studies in China
  • Strategies on how to adapt and restructure current business models to this industry
 
This report tackles key concerns to the Chinese biopharmaceutical market such as:
  • Lack of regulatory policy and legislation 
  • Reimbursement schemes and payers concerns
  • Funding and government sponsorship issues
  • International scepticism of Chinese safety and efficacy therapeutic profiles
 
This report will tell you if the companies mentioned are:
 
  • Strong, competitive players
  • Pooling their resources for specific growth and therapeutic areas
  • Investing strategically in R&D
  • Have a history of strategic M&A activity
1.0 Summary 
1.1 Objectives of Report 
1.2 Scope of Study 
1.3 Data Sources and Methodology 
1.4 Key Findings and Observations 
1.5 Executive Summary 
 
2.0 Chronic Disease Prevalence Statistics 
 
3.0 Business Environment 
3.1 Economic Indicators, Trade Policy and Merchandise and Commercial Trade Statistics 
3.2 Gross Domestic Product of China, Historic and Projection Analysis 
3.3 Annual Health Expenditure in China, Historic and Projected Analysis 
3.4 Global and Chinese Economic Outlook 2010-2013 
3.5 Chinese Economic Outlook in Comparison to Emerging Markets and Developing Countries 
3.6 Chinese Economic Outlook in Comparison to Advanced Economies (US, Europe) 
 
4.0 Chinese Pharmaceutical Market 
4.1 Market Overview 
4.2 Main Players in China’s Pharmaceutical Industry 
4.3 Anti-Allergic Drug Market 
4.4 Asthma Drug Market 
4.5 Benign Prostate Hyperplasia Drug Market 
4.6 Anti-depressant Drug market 
4.7 Dermatitis Drug Market 
4.8 Diabetic Drug Market 
4.9 Hypertension Drug Market 
4.10 Dyslipidaemia Drug Market 
4.11 Senile Dementia Drug Market 
4.12 Cancer Drug Market 
4.13 Rheumatoid Arthritis Drug Market 
4.14 Ophthalmological Drug Market 
4.15 Liver Disease Drug Market 
4.16 Antibiotic Drug Market 
 
5.0 Government and Regulation Environment 
5.1 12th Five Year Plan 
5.2 Intellectual Property for Pharmaceuticals in China 
5.3 State Food and Drug Administration (SFDA) 
5.4 Pharmaceutical Distribution Process in China 
 
6.0 China – Third Largest Pharma Market 2012 
6.1 China – At the Forefront of Emerging Markets 
6.2 Generic Medication Market and China 
6.3 Novel Product Drug development 
6.4 Drug Development Cost (Change heading) 
6.5 Drug Development Case Study - Beijing Continent Pharmaceuticals 
6.6 China’s Pharmaceutical Export Market 
6.7 Spot Light - China Medical City Taizhou 
 
7.0 Global Pharmaceutical Companies Interest in China 
7.1 Abbott China 
7.2 AstraZeneca China 
7.3 AstraZeneca Products in China 
7.4 Boehringer Ingelheim China 
7.5 Eli Lilly China 
7.6 GlaxoSmithKline China 
7.7 Johnson & Johnson Medical China 
7.8 Merck China 
7.9 Novartis China 
7.10 Pfizer China 
7.10.1 Pfizer China R&D Centre 
7.10.2 Pfizer China Products 
7.11 Roche China 
 
8.0 Chinese Pharmaceutical Companies 
8.1 Amoytop Biotech 
8.2 Active Pharmaceutical Products 
8.2.1 Research and Development 
8.2.2 Financial Information 
8.3 Beijing Continent Pharmaceuticals 
8.4 FusoGen Pharmaceuticals 
8.4.1 Financial Information 
8.5 Shanghai Huaguan Biochip 
8.5.1 Financial Information 
8.6 SiBiono GeneTech 
8.6.1 Financial Information 
8.7 Sinovac Biotech 
8.7.1 Financial Information 
8.7.2 New Products 
8.7.3 Split viron pandemic influenza vaccine 
8.7.4 RabEnd 
8.7.5 Pipeline Portfolio 
8.7.6 EV71 virus Vaccine 
8.7.7 Pneumococcal Conjugate Vaccine 
8.7.8 Pneumococcal Polysaccharide Vaccine 
8.7.9 Varicella Vaccine 
8.7.10 Measles, Mumps and Rubella Vaccines 
8.7.11 Rotavirus Vaccine 
 
9.0 Drivers, Restraints, Challenges and Opportunity Analysis 
9.1 Key Drivers of the Biopharmaceutical Market in China 
9.2 Key Restraints of the Biopharmaceutical Market in China 
9.3 Challenges of the Pharmaceutical Industry in China 
9.4 Opportunities Within BioPharma China
Table 2.1: Most Prominent Cancer Manifestations in China 
Table 2.2: Top Fifty Diseases in China Today (non-cancer) 
Table 2.3: Top Infectious Disease States in China Today 
Table 3.1: World Trade Organisation Basic Indicators on China 
Table 3.2: World Trade Organisation Trade Policy of China 
Table 3.3: World Trade Organisation Merchandise Trade Statistics: China 
Table 3.4: World Trade Organisation Commercial Services Trade Statistics: China 
Table 3.5: Summary of International Monetary Fund Members’ Quota, Reserve Position, SDR Holdings, Outstanding Credit, Recent Lending Arrangements, Projected Payments Due and Monthly Historical Transactions of China 
Table 3.6: China Statistics 
Table 4.1: Top Global Pharma Markets 2003-2013 
Table 4.2: Major Players in China’s Anti-Allergy Drug Market 
Table 4.3: Major Players in China’s Asthma Drug Market 
Table 4.4: Major Players in China’s Benign Prostate Hyperplasia (BPH) Drug Market 
Table 4.5: Major Players in China’s Anti-Depressant Drug Market 
Table 4.6: Prescription Dermatitis Drug Industry Sub-Markets and Associated Therapeutics 
Table 4.7: Top Prescription Dermatitis Drugs on the Chinese Market 
Table 4.8: Major Players in China’s Dermatitis Drug Market 
Table 4.9: Major Players in China’s Diabetic Drug Market 
Table 4.10: Major Players in China’s Hypertension Drug Market 
Table 4.11: Major Players in China’s Dyslipidaemia Drug Market 
Table 4.12: Major Players in China’s Senile Dementia Drug Market 
Table 4.13: Major Players in China’s Cancer Drug Market 
Table 4.14: Major Players in China’s Rheumatoid Arthritis Drug Market 
Table 4.15: Major Players in China’s Ophthalmological Drug Market 
Table 4.16: Major Players in China’s Liver Disease Drug Market 
Table 4.17: Major Players in China’s Antibiotic Drug Market 
Table 5.1: Seven Strategic Emerging Industries of China’s 12th Five Year Plan 2011-2015 
Table 5.2: Outline of the Chinese Promotion Plan for the Implementation of the National Intellectual Property Strategy, 2012 
Table 5.3: Challenges facing the Pharmaceutical Distribution Business in China 
Table 5.4: Prescription Drug Sales Distribution Channels in China 
Table 6.1: Major Biogeneric Products in China 
Table 6.2: Imported Therapeutics with Administrative Protection in China 
Table 6.3: Expired Proprietary Biopharmaceuticals in China 
Table 6.4: Reasons Why Multinational Companies Seek CMO’s in China 
Table 6.5: Comparison of Clinical Trial Cost between China and the USA 
Table 6.6: Five Functional Districts of China Medical City 
Table 6.7: Five Key R&D and Manufacturing Areas within China Medical City 
Table 7.1: Top Multinational Company Performance, China 2011 Q1 
Table 7.2: Abbott Areas of Expertise 
Table 7.3: Abbott Key Global Products 
Table 7.4: Abbott China Anaesthesia Product Profile 
Table 7.5: Abbott China Cardiovascular Product Profile 
Table 7.6: Abbott China Vaccine Product Profile 
Table 7.7: Abbott China Digestion Product Profile 
Table 7.8: Abbott China HIV Product Profile 
Table 7.9: Abbott Rheumatology HIV Product Profile 
Table 7.10 Abbott China Gynaecological Product Profile 
Table 7.11 Abbott China Urological Product Profile 
Table 7.12 Abbott China Liver Disease Product Profile 
Table 7.13 Abbott China Diagnostic Product Profile 
Table 7.14:Abbott China Molecular Diagnostic Product Profile 
Table 7.15: Abbott Blood Glucose Meter Product Profile 
Table 7.16: Abbott Cardiovascular Product Profile 
Table 7.17: Abbott Rapid Bedside Diagnostic/ Point of Care Product Profile 
Table 7.18: Important Milestones in AstraZeneca China’s History 
Table 7.19: AstraZeneca China Anaesthetic Range of Products 
Table 7.20: AstraZeneca China Cardiovascular and Metabolism Range of Products 
Table 7.21: AstraZeneca China Gastrointestinal Range of Products 
Table 7.22: AstraZeneca China Infection Range of Products 
Table 7.23: AstraZeneca China Neurology Range of Products 
Table 7.24: AstraZeneca China Oncology Range of Products 
Table 7.25: AstraZeneca China Respiratory Range of Products 
Table 7.26: Bayer China Important Milestones 
Table 7.27: Bayer - Leading Therapeutics in China 
Table 7.28: Therapeutic Areas Covered by Bayer Healthcare Pharmaceuticals in China 
Table 7.29: Boehringer Ingelheim Major Products in China 
Table 7.30: Main Therapeutic Areas of Interest to Boehringer Ingelheim China 
Table 7.31: Global Therapeutic Pipeline, Boehringer Ingelheim 
Table 7.32: Major Global Boehringer Ingleheim Therapeutic Products 
Table 7.33: GlaxoSmithKline Prescription Portfolio and Indications in China 
Table 7.34: GlaxoSmithKline Vaccine Portfolio and Indications in China 
Table 7.35: GlaxoSmithKline Over the Counter Portfolio and Indications in China 
Table 7.36: Significant Milestones in Johnson and Johnson China History 
Table 7.37: Merck Serono Pharmaceutical Key Therapeutic Areas in China 
Table 7.38: Merck Serono Fertility and Infertility Therapeutic Portfolio in China 
Table 7.39: Merck Serono Therapeutic Portfolio in China 
Table 7.40: Merck Pharmaceutical Hong Kong Therapeutic Portfolio 
Table 7.41: Range of Diabetic Products from Novo Nordisk China 
Table 7.42: QUICKFACTs - Pfizer China 
Table 7.43: Important Milestones – Pfizer China 
Table 7.44: Pfizer China – Range of Infectious Disease Therapeutics for Chinese Health Care Market 
Table 7.45: Pfizer China – Range of Mental Health Products for Chinese Health Care Market 
Table 7.46: Pfizer China – Range of Genitourinary Products for Chinese Health Care Market 
Table 7.47: Pfizer China – Range of Endocrine Products for Chinese Health Care Market 
Table 7.48: Pfizer China – Range of Women’s Health Products for Chinese Health Care Market 
Table 7.49: Pfizer China – Range of Cardiovascular Disease Products for Chinese Health Care Market 
Table 7.50: Pfizer China – Range of Oncology Products for Chinese Health Care Market 
Table 7.51: Pfizer – Key Consumer Healthcare Global Products 
Table 7.52: Pfizer – Key Speciality Care Global Products 
Table 7.53: Pfizer – Key Oncology Global Products 
Table 7.54: Pfizer – Key Global Established Products 
Table 7.55: Pfizer – Key Innovative Products in Emerging Markets 
Table 7.56: Pfizer – Key Animal Health Global Products 
Table 7.57: Roche Pharmaceuticals Product List in China 
Table 7.58: Seven Growth Platforms of Sanofi China 
Table 7.59: Key Therapeutic Areas of Sanofi China 
Table 8.1: Important Milestones in Amoytop Biotech’s Development 
Table 8.2: Current Recombinant protein therapeutics by Amoytop Biotech 
Table 8.3: Active Pharmaceutical Product Portfolio of Amoytop Biotech 
Table 8.4: Milestones Achieved by FusoGen Pharmaceuticals 
Table 8.5: Research and Development Sub-groups of FusoGen Pharmaceuticals 
Table 8.6: Shanghai Huaguan Biochip Rapid Test Portfolio 
Table 8.7: Shanghai Huaguan Biochip Laboratory Service Portfolio 
Table 8.8: Intracellular Functions of the Gene Therapy Agent, Gendicine by SiBono GeneTech 
Table 8.9: Gendicine - Potential Oncology Indications for Future Approval 
Table 8.10: Current Human Vaccine Portfolio of Sinovac Biotech 
Table 8.11: Important Milestones in the History of Sinovac Biotech 
Table 8.12: Pipeline Portfolio of Sinovac Biotech 
Table 8.13: Total Sales Figures Sinovac Biotech 2007-2011 
Table 9.1: Key Drivers of the Biopharmaceutical Market in China 
Table 9.2: Key Restraints of the Biopharmaceutical Market in China 
Table 9.3: Key Challenges of the Pharmaceutical Market in China 
Table 9.4: Patent Expirations of Selected Top Brand Name Therapeutics by 2020 
Table 9.5: Leading Biopharmaceutical Areas with Significant Opportunities in China 
Figure 2.1: Proportional (%) Mortality Rate of Total Deaths in China, All Ages 
Figure 3.1: China GDP Figures 2006-2015 
Figure 3.2: Annual Health Expenditure in China 2006-2015 
Figure 3.3: Global and Emerging Market and Developing Countries Economic Growth Change 2010-2013 
Figure 3.4: Global, Emerging Market and Developing Countries and China Economic Growth Change 2010-2013 
Figure 3.5: Global, Emerging Market and Developing Countries and Russia Economic Growth Change 2010-2013 
Figure 3.6: Global, Emerging Market and Developing Countries and India Economic Growth Change 2010-2013 
Figure 3.7: Global, Emerging Market and Developing Countries and Brazil Economic Growth Change 2010-2013 
Figure 3.8: Global, US and Germany Economic Growth 2010-2013 
Figure 3.9: US and UK Gross Domestic Product per capita Forecast 2010-2017 
Figure 3.10: Global, France and Italy Economic Growth 2010-2013 
Figure 3.11: France, Germay and Italy Gross Domestic Product per capita Forecast 2010-2017 
Figure 3.13: Global, Japan and Canada Economic Growth 2010-2013 
Figure 3.14: China, Brazil and India Gross Domestic Product per capita Forecast 2010-2017 
Figure 4.1: The Chinese Healthcare Industry by Sector, 2011 
Figure 4.2: Anti-Depressant Market Share, China 2009 Figures (Percentage) 
Figure 5.1: Projected Figures of Strategic Emerging Industry GDP Percentage Contribution 2011-2020 
Figure 5.2: State Drug and Food Administration, China, Application and Approval Procedure for Imported Drugs 
Figure 5.3: State Drug and Food Administration, China, Application and Approval Procedure for Clinical Trials 
Figure 5.4: Revenue Share (Percentage) of Major Players in Chinese Pharmaceutical Distribution Market 
Figure 5.5: Revenue Share (Billion $) of Major Players in Chinese Pharmaceutical Distribution Market 
Figure 6.1: Three Tier ‘Pharmerging’ Markets with Potential for Significant Growth 
Figure 6.2: Number of Investigational New Drug Applications in China 2003-2010 
Figure 6.3: Number of New Drug Applications in China 2003-2010 
Figure 6.4: Current Number of Novel Therapeutics in Phase I, Phase II and Phase III Clinical Trials in China 
Figure 6.5: Percentage of Clinical Trial Drug by Disease State 
Figure 6.6: China’s Regional Pharmaceutical Processing Trade Export Market Share Percentage 2010 
Figure 6.7: Contract Amount of China’s Regional Pharmaceutical Processing Trade Export, 2010 
Figure 6.8: Top Five Contract Pharmaceutical Export Markets of China, 2010 
Figure 7.1: Abbottt – Business Specialization Strategy 2012: Diversified Medical Products and Research-Based Pharmaceuticals 
Figure 7.2: Abbott Diversified Medical Product Portfolio 
Figure 7.3 Business Sectors – Pfizer China 
Figure 8.1: FusoGen Pharmaceuticals Product Pipeline and Clinical Trial Progression 
Figure 8.2: Shanghai Huaguan Biochip Serial Analysis of Gene Expression (SAGE) Service 
Figure 8.3: Total Sales Figures Sinovac Biotech 2007-2011 
Figure 8.4: Percentage of Sales Attributed to Healive Vaccine, 2009-2011 
Figure 8.5: Reported Sales of Healive Vaccine, 2009-2011 
Figure 8.6: Reported Sales of Bilive Vaccine, 2009-2011 
Figure 8.7: Reported Sales of Anflu Vaccine, 2009-2011 
Figure 8.8: Reported Sales of Panflu Vaccine, 2009-2011 
Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +